Dialysis Treatment Articles & Analysis
14 news found
The FDA approval is based on positive six-month results from the ILLUMINATE-C Phase 3 study, in which OXLUMO treatment resulted in substantial reductions in POx and demonstrated an encouraging safety and tolerability profile in patients with compromised renal function, including those with kidney failure and undergoing treatment by hemodialysis. ...
Approximately half of patients with high-level BK viremia develop BKV nephropathy (BKVN), which can lead to decreased kidney survival and a return to end-stage renal disease and dialysis. There are no approved or effective antiviral treatments for BK viremia. ...
ByKalaris
There are currently 3.3 million haemodialysis patients worldwide who receive treatment multiple times a week. Dialysis treatment can reduce life expectancy by two thirds and almost half of patients die from cardiovascular complications, in part caused by the immune system reacting to components of the dialysis apparatus. The ...
Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in haemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard technology. ...
(Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a new sterilization method of the cartridge utilized in its Tablo® Hemodialysis System, enabling full production in North America. The Tablo cartridge is a single-use ...
The FDA previously granted RMAT and orphan drug designations (ODD) to posoleucel for the treatment of hemorrhagic cystitis (HC) caused by BKV in adults and children following allo-HCT. The European Medicines Agency has granted posoleucel PRIority Medicines (PRIME) designation for the treatment of serious infections with AdV, BKV, CMV, EBV and HHV-6, and Orphan ...
ByKalaris
View the full release here: https://www.businesswire.com/news/home/20211118005835/en/ Outset is reinventing how dialysis is delivered to patients. Specifically designed to simplify dialysis treatment for patients and providers, the Tablo® Hemodialysis System is a first-of-its-kind enterprise solution that is approved for use across the ...
These data underscore the potential of nedosiran to be a meaningful treatment option for those affected by PH1, if approved.” Separately, findings from a real-world study examining de-identified electronic medical record (EMR) data, including demographics, clinical characteristics and healthcare utilization among 47 patients with PH pre- and post-dialysis ...
CloudCath, developer of a remote monitoring and predictive analytics platform for catheter-based treatments, today announced a collaboration with American Renal Associates (ARA), a leading provider of outpatient dialysis services. In a U.S.- based, pre-market clinical study, ARA will evaluate the use of CloudCath’s System by peritoneal ...
For particularly ill patients with COVID-19, the virus can cause acute kidney failure which can eventually turn into chronic kidney failure – with the only treatment options being either lifelong dialysis or a kidney transplant. ...
The Ellipsys® Vascular Access System enables patients with kidney failure to start dialysis treatment sooner with fewer procedures, complications and interventions compared to surgery, according to several leading physicians who spoke at the recent meeting of the American Society of Diagnostic and Interventional Nephrology (ASDIN). ...
A landmark two-year follow-up study on the Ellipsys® Vascular Access System was highlighted at the annual Controversies in Dialysis Access (CiDA) meeting, one of the premier dialysis access medical conferences in the world. ...
A significant advancement for dialysis patients and clinicians, the Ellipsys System, developed by Avenu Medical (San Juan Capistrano, CA), transforms an open surgery connecting an artery to a vein into a minimally invasive procedure using a needle and a catheter. ...
The absence of clinical symptoms until late stages makes diagnosis and treatment difficult. Sri Lanka has reported a spurt in CKD cases since the 1990s with 80 percent of patients ending up with total kidney failure within two years of diagnosis. Treatment – dialysis or organ transplantation – being costly, death becomes inevitable ...